| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.74 KB | License | |||
| 267.69 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
The Introduction of high-throughput technologies in breast cancer enabled the recognition of groups with prognostic value, in which target-therapies can be applied. However, a relevant percentage of patients show no clinical benefit. A possible solution could be the inhibition of pathways that are common in all tumor subtypes. Alterations of the serine-threonine kinase mammalian target of rapamycin (mTOR) signaling pathway are common in cancer and thus mTOR is being pursued as a therapeutic agent.
Description
Keywords
Pedagogical Context
Citation
Martins, D., & Schmitt , F. (2015). Studies to identify potential biomarkers for screening, diagnosis and therapy: breast cancer model. In R. A. Silva, P. Baylina, F. Q. Vieira, C. Barrias, M. Rubim, T. Coelho, C. Prudêncio, & Â. Jesus (Eds.), II Congresso Internacional da Saúde Gaia Porto: Livro de Resumos (pp. 32 - 33). Escola Superior de Tecnologia da Saúde do Instituto Politécnico do Porto.